Inflammatory Markers During Early Treatment of Seroconverters in a Randomized Placebo-Controlled Trial of PrEP (ANRS-IPERGAY)
| Autor: | Jean-Michel Molina, Sylvain Chawki, Diane Carette, Claire Pintado, Laurence Meyer, Laurent Cotte, Isabelle Charreau, Audrey Gabassi, Marie-Laure Chaix, Constance Delaugerre, Gilles Pialoux, Eric Cua |
|---|---|
| Přispěvatelé: | Laboratoire de Virologie [CHU Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Génomes, biologie cellulaire et thérapeutiques (GenCellDi (U944 / UMR7212)), Collège de France (CdF (institution))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Archet 2 [Nice] (CHU), Service de Maladies Infectieuses et Tropicales [Hôpital de la Croix-Rousse - HCL], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service de Maladies infectieuses et tropicales [CHU Tenon], CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de maladies infectieuses et tropicales [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Cité (UPCité), Gestionnaire, Hal Sorbonne Université, Génomes, biologie cellulaire et thérapeutiques (GenCellDi (UMR_S_944)), Collège de France (CdF (institution))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Service des maladies infectieuses et tropicales [CHU Tenon], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université de Paris (UP) |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
[SDV]Life Sciences [q-bio] Placebo-controlled study Human immunodeficiency virus (HIV) D-dimers Inflammation 030204 cardiovascular system & hematology medicine.disease_cause Early initiation 03 medical and health sciences Pre-exposure prophylaxis 0302 clinical medicine Internal medicine medicine 030212 general & internal medicine Interleukin 6 biology business.industry HIV sCD14 Antiretroviral therapy Inflammatory biomarkers IL6 PrEP 3. Good health [SDV] Life Sciences [q-bio] Infectious Diseases AcademicSubjects/MED00290 Oncology biology.protein Brief Reports medicine.symptom early antiretroviral therapy business CRP |
| Zdroj: | Open Forum Infectious Diseases Open Forum Infectious Diseases, 2021, 8 (3), pp.ofab085. ⟨10.1093/ofid/ofab085⟩ Open Forum Infectious Diseases, Oxford University Press, 2021, 8 (3), pp.ofab085. ⟨10.1093/ofid/ofab085⟩ |
| ISSN: | 2328-8957 |
| Popis: | HIV-related inflammation is associated with poor outcomes. We describe inflammatory biomarkers in 17 participants in a pre-exposure prophylaxis trial who seroconverted with very early initiation of antiretroviral therapy. Inflammation peaked at the time of HIV infection and returned to baseline within 6–12 months. Starting antiretroviral therapy very early could help mitigate long-lasting HIV-related inflammation. In seventeen HIV-seroconverters in a PrEP trial who were treated very early on, inflammation peaked at the time of HIV-infection and returned to pre-HIV-infection levels within twelve months. Starting antiretroviral therapy very early could help mitigate long-lasting HIV-related inflammation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|